LOS ANGELES, July 11, 2006 (PRIMEZONE) -- Universal Detection Technology (OTCBB:UDTT) (FWB:PO8), a developer of early-warning monitoring technologies to protect people from bio-terrorism and other infectious health threats, announced today that one of its consultants, Joseph Breen & Associates has initiated talks with the Pentagon on its behalf.
"The United States Government is one of the largest employers and facility managers in the world, maintaining over 490,000 federally owned or controlled buildings." Joseph Breen, President of Breen & Associates added, "As such, cutting edge technologies that offer early detection of potential biological attacks at a government facility remains a key priority.
"Through the use of the technology offered by Universal Detection Technology, the Government will be able to employ a system that provides high function at a fraction of the costs incurred by other systems currently employed. This would allow for greater use of taxpayer dollars while providing increased protection of the public."
"We hope to market and sell our products and services to the U.S. Government and agencies with the help of our consultants and partners," said Jacques Tizabi, UDTT's Chief Executive Officer. "We retained Joseph Breen & Associates for help with obtaining a GSA contract and with marketing to U.S. Government agencies. We consider Breen a powerful ally and expect to use their expertise in better marketing our counter-bio-terror solutions," he added.
About Breen & Associates
Breen & Associates is a government contracting sales consulting firm based in Washington, DC. For companies looking for entry into the government market, Breen & Associates provides assistance in complete program development, Strategic implementation, and follow-on sales, marketing, and administrative services.
About Universal Detection Technology
Universal Detection Technology (UDTT), founded in 1973, is a developer of monitoring technologies, including bio-terrorism detection devices. Universal Detection Technology, in cooperation with NASA's Jet Propulsion Laboratory (JPL) has developed the BSM-2000, a bacterial spore and anthrax spore monitoring device, which combines JPL's spore detection technology with UDTT's aerosol capture device. For more information, please visit http://www.udetection.com.
Forward-Looking Statements
Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties include, among other things, the funding of amounts of capital adequate to provide for our working capital needs and our timely repayment of debt; our ability to timely and cost effectively complete the development and testing of our products; our ability to commercially produce our products on a profitable basis; commercial acceptance of our products; product price volatility; product demand; market competition and general economic conditions and; other factors described in UDTT's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.